Bio-Techne (TECH) to Release Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) will likely be announcing its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $285.84 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Bio-Techne Price Performance

Bio-Techne stock opened at $72.05 on Tuesday. The stock has a market capitalization of $11.45 billion, a P/E ratio of 76.65, a P/E/G ratio of 5.42 and a beta of 1.27. The company’s fifty day moving average price is $74.67 and its 200 day moving average price is $74.38. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 4.56. Bio-Techne has a 1 year low of $61.16 and a 1 year high of $85.57.

Analyst Ratings Changes

TECH has been the subject of a number of research reports. Robert W. Baird boosted their target price on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. StockNews.com upgraded Bio-Techne from a “hold” rating to a “buy” rating in a research note on Tuesday, November 12th. Finally, Scotiabank raised their target price on Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $84.00.

Insider Activity

In other news, CEO Kim Kelderman sold 13,392 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the completion of the sale, the chief executive officer now owns 39,004 shares in the company, valued at $3,014,619.16. This trade represents a 25.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.90% of the company’s stock.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.